European Commission expands Opdivo approval for lung and kidney cancer
The European Commission has approved new indications for Bristol-Myers Squibb's Opdivo (nivolumab) monotherapy, expanding its use in the treatment of non-small-cell lung cancer (NSCLC), and adding the indication of renal cell carcinoma (RCC).
The drug is already approved in Europe for use in previously treated patients with metastatic squamous NSCLC.
Opdivo's indication has now been expanded to include non-squamous NSCLC, which represents 85% of lung cancer cases, and monotherapy for locally advanced or metastatic disease.
Click on this link for more information.
